The air hung heavy with the scent of mahogany and desperation in Eleanor Vance-Hawthorne’s office.  Sunlight sliced through the floor-to-ceiling windows, highlighting the dust motes swirling in the stagnant air. Outside, the bustling city of Neo-London pulsed with life, oblivious to the crisis brewing within these walls.

Eleanor, her silver hair pulled back into a severe bun, tapped a manicured finger against the mahogany desk – her father’s desk, no less. The nameplate on it read simply “Hawthorne Enterprises,” a legacy she had inherited and was now desperately trying to salvage. 

Six months ago, the company had been riding high. A leading force in bio-engineering, they were poised for a breakthrough that would revolutionize medicine. Then came Project Chimera, a disastrous attempt to genetically engineer a self-healing organ, which resulted in a catastrophic lab leak and public panic.

Now, Hawthorne Enterprises teetered on the brink of collapse, facing lawsuits, government scrutiny, and dwindling investor confidence. Eleanor knew she was running out of time. This wasn’t just about money; it was about her family name, her father's legacy, and the future of a company that held the potential to heal the world. 


